The fact that covering GLP-1s under Medicare Part D for authorized uses is already making a mark on total Part D program spending could be a sign of even higher spending to come as Part D plans are now able to cover Wegovy for its heart health benefits, and if new uses for GLP-1s are approved
Klonoff DC
Muscle Injury Research Muscle injuries like strains, contusions, and lacerations are common and frustrating to manage
Certain limitations need consideration
At the level of individual MACE components, GLP-1 RAs also reduced CV mortality (by 13%, P = 0.016), nonfatal stroke (by 16%, P = 0.007), and nonfatal MI (by 9%, but statistically non-significant)
It supports healing from ulcers, leaky gut syndrome, IBS, and other inflammatory bowel issues